Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Markers Shown to Predict Efficacy of Ovarian Cancer Therapy

NEW YORK, March 19 - Results of a study conducted by oncology researchers show that genomic markers can predict the success of ovarian cancer treatment.

 

The study, presented on Tuesday at the Society of Gynecologic Oncologists meeting, held in Miami Beach, Fla., sought to identify markers that could help predict patient response to a common chemotherapeutic treatment for advanced epithelial ovarian cancer.

 

Researchers led by Mayo Clinic oncologist Lynn Hartmann and Edwin Clark of Millennium Pharmaceuticals' Predictive Medicine division compared 51 samples from advanced ovarian cancer tumors. The tumors that recurred within 21 months were deemed drug-resistant, and those that did not reappear for more than 21 months were considered sensitive to the therapy.

The mRNA expression levels of each of 30,000 genes was analyzed using Millennium cDNA arrays, generating more than 1.5 million data points. The team analyzed the results to identify a subset of genes that were most closely correlated with drug response.

 

The team then applied this information to a separate set of 28 tumor samples, and ultimately came up with a set of 14 candidate genes that could predict tumor sensitivity with 86 percent accuracy.

 

The results "need to be corroborated in other sample sets from ovarian cancer patients," Hartmann said in a statement. Nonetheless, she said, the study suggests that pharmacogenomic approaches may be useful in the treatment of this cancer.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.